MK-4482 (Molnupiravir, EIDD-2801) is an orally administered nucleoside analog antiviral compound, after being converted into an active metabolite in vivo, it can inhibit coronavirus replication by inducing viral RNA replication errors.
Some Studies and clinical practice have shown that this mechanism has a significant inhibitory effect on feline coronaviruses that cause by FIP virus. Molnupiravir can be used as a first-line or alternative or rescue regimen for FIP, it is suitable for wet, dry, and mixed FIP cases. In addition, it is conveniently administered orally with high compliance. Multiple case studies have shown that, it can significantly improve clinical symptoms, laboratory indicators, and long-term survival rates. It is well-tolerated when used under veterinary guidance and has become an important option in the antiviral treatment of FIP.
As you know, GS-441524 has considered the standard antiviral treatment for FIP, with a rich clinical data base and high success rate. Molnupiravir has shown similar success rates (approximately 70–85%) to GS-441524 in multiple cases, and is less expensive.
It is used as an antiviral option for the management of feline infectious peritonitis, it works by inhibiting replication of feline coronavirus (FCoV).
It is suitable for wet, dry, and mixed forms of cat FIP.
It can be applied as a primary treatment, or as a rescue/alternative therapy in relapsed or refractory FIP cases.
Q1: What is the brand name of Molnupiravir (EIDD-2801)?
A1: The brand name of Molnupiravir (EIDD-2801) is FIPNOPE.
Q2: Where is FIPNOPE Molnupiravir manufactured?
A2: It is manufactured in China.
Q3: What is the minimum order?
A3: The minimum order quantity is 50 tablets.
Q4: How is packaged and what is the delivery time?
A5: Molnupiravir is packaged with 10 tablets per plate, and the delivery time is 8-13 days.
